Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated 1 day ago
Cardiac medtech HeartBeam drops CEO in restructuring aimed at global ECG platform push
1 day ago
HeartBeam, the maker of a cable-free ECG system, moved CEO Robert Eno...
Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says
1 day ago
Epicrispr Biotechnologies has used its gene silencing tech to boost muscle mass...
Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout
1 day ago
Biogen isn’t wasting any time integrating its multibillion-dollar purchase of Apellis, revealing...
The deal before the deal
1 day ago
Before a biotech deal gets signed, companies are already being tested by...
Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells
1 day ago
Moderna has unveiled its first in vivo CAR-T program. Building on other...
Chutes & Ladders—EMD Serono taps in new commercial strategy head
1 day ago
EMD Serono, Merck KGaA’s North American healthcare arm, has promoted from within...
How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery
1 day ago
Upon finally reaching the clinic, iBio feels vindicated about the artificial intelligence-powered...
Puerto Rico makes its case as a biotech manufacturing hub
1 day ago
Puerto Rico is building on its pharma manufacturing legacy to attract advanced...
Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy
1 day ago
In a recent interview with Fierce, Fosun Pharma co-president, Xinli Wang, M.D...
BIO 2026: How a gut feeling transformed cancer treatment forever
2 days ago
Dr. Israel Lowy remembers the days when he and his oncology immunotherapy...
Otsuka posts phase 3b ADHD trial win ahead of looming FDA approval decision
2 days ago
A phase 3b trial of Otsuka’s attention-deficit/hyperactivity disorder prospect has hit its...
With $15M discovery deal, Boehringer becomes latest Big Pharma to buy into Immunai’s AI platform
2 days ago
TechBio outfit Immunai is continuing its parade of Big Pharma partnerships with...